Article
Rheumatology
Zhixiu Li, Mohammad Kazim Khan, Sjef M. van der Linden, Bjorn Winkens, Peter M. Villiger, Heinz Baumberger, Hermine van Zandwijk, Muhammad Asim Khan, Matthew A. Brown
Summary: This study found that patients with ankylosing spondylitis (AS) have a higher mortality rate compared to the general population, and healthy individuals carrying the HLA-B27 gene also have a similar risk. Additionally, female patients have a lower life expectancy. However, in the overall European population, the presence of the HLA-B27 gene does not affect survival or the risk of death from cardiovascular disease.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Victoria Navarro-Compan, Alexandre Sepriano, Bassel El-Zorkany, Desiree van der Heijde
Summary: Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the axial skeleton, leading to symptoms such as chronic back pain and spinal stiffness. Diagnosis relies on recognizing clinical patterns and utilizing clinical, laboratory, and imaging features. Treatment options include non-steroidal anti-inflammatory drugs as first-line therapy, with biologics as a second-line option, showing efficacy in improving disease symptoms.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Haseeb Chaudhary, Clementina Lopez-Medina, Muhammad Asim Khan, Maxime Dougados, Marina Magrey
Summary: In a global axSpA cohort, HLA-B*27 (-) patients had a longer delay in diagnosis, more frequently had peripheral arthritis, enthesitis, IBD, and psoriasis, and were more often treated with csDMARDs compared to the HLA-B*27 (+) subgroup.
Article
Rheumatology
Xabier Michelena, Sizheng Steven Zhao, Sayam Dubash, Linda E. Dean, Gareth T. Jones, Helena Marzo-Ortega
Summary: This study aimed to describe the baseline characteristics, bDMARD response and drug survival of axSpA patients in the UK according to radiographic status. Results showed comparable levels of biologic response and drug survival between nr-axSpA and r-axSpA patients.
Article
Rheumatology
Zhixiu Li, Sjef M. van der Linden, Muhammad Asim Khan, Heinz Baumberger, Hermine van Zandwijk, Mohammad Kazim Khan, Peter M. Villiger, Matthew A. Brown
Summary: The objective of this study is to assess heterogeneity in axial spondyloarthritis (axSpA) and its sources. The results suggest that women clinically diagnosed with axSpA but without radiographic sacroiliitis have distinct characteristics compared to men with non-radiographic axSpA.
Article
Medicine, General & Internal
Yu-Hao Lee, Shih-Wei Huang, Chih-Kuang Chen, Jia-Pei Hong, Yi-Wen Chen, Hui-Wen Lin
Summary: This study investigated the risk of dementia in axSpA patients and the role of csDMARDs in reducing the risk. The results showed that axSpA patients had a higher risk of vascular dementia, but the use of csDMARDs did not significantly affect the risk of dementia.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Elena Nikiphorou, Pedro D. Carvalho, Annelies Boonen, Bruno Fautrel, Pascal Richette, Pedro M. Machado, Desiree van der Heijde, Robert Landewe, Sofia Ramiro
Summary: This study investigated sick leave occurrence in early axSpA patients, finding that male gender and higher education were associated with lower risk of SL, while higher disease activity, older age, smoking, and use of TNF inhibitors were associated with higher risk of SL.
Article
Rheumatology
Adrian Ciurea, Andrea Gotschi, Seraphina Kissling, Alexander Bernatschek, Kristina Burki, Pascale Exer, Michael J. Nissen, Burkhard Moller, Almut Scherer, Raphael Micheroli
Summary: This study compared the characteristics of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and found differences in demographic and clinical features between the two groups, but a similar disease burden.
Article
Rheumatology
Murat Torgutalp, Valeria Rios Rodriguez, Ani Dilbaryan, Fabian Proft, Mikhail Protopopov, Maryna Verba, Judith Rademacher, Hildrun Haibel, Joachim Sieper, Martin Rudwaleit, Denis Poddubnyy
Summary: This study aimed to analyze the association between treatment with tumour necrosis factor inhibitors (TNFi) and radiographic spinal progression in patients with axial spondyloarthritis (axSpA). The results showed that TNFi treatment in the current 2-year interval was not associated with retardation of radiographic spinal progression, but TNFi treatment in the previous 2-year interval was significantly associated with a reduction of mSASSS progression.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Rosaline van den Berg, Desiree van der Heijde, Floris A. van Gaalen
Summary: The objective of this study was to assess the construct validity of the CT Syndesmophyte Score (CTSS) for measuring structural spinal damage in patients with radiographic axial spondyloarthritis. The study compared the scores of CTSS and modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in detecting syndesmophytes and their correlation with spinal mobility. The results demonstrated good agreement between CTSS and mSASSS in detecting syndesmophytes, and higher correlation of CTSS with spinal mobility measures.
Article
Rheumatology
Michael Nissen, Benedicte Delcoigne, Daniela Di Giuseppe, Lennart Jacobsson, Merete Lund Hetland, Adrian Ciurea, Lucie Nekvindova, Florenzo Iannone, Nurullah Akkoc, Tuulikki Sokka-Isler, Karen Minde Fagerli, Maria Jose Santos, Catalin Codreanu, Manuel Pombo-Suarez, Ziga Rotar, Bjorn Gudbjornsson, Irene Van der Horst-Bruinsma, Anne Gitte Loft, Burkhard Moeller, Herman Mann, Fabrizio Conti, Gozde Yildirim Cetin, Heikki Relas, Brigitte Michelsen, Pedro Avila Ribeiro, Ruxandra Ionescu, Carlos Sanchez-Piedra, Matija Tomsic, Arni Jon Geirsson, Johan Askling, Bente Glintborg, Ulf Lindstroem
Summary: This multicenter study of axSpA patients found similar one-year treatment outcomes between TNFi monotherapy and csDMARD co-therapy. Heterogeneity across countries limited the identification of specific subgroups, such as peripheral arthritis, that may benefit from co-therapy.
Article
Rheumatology
Arvind Ganapati, Mahasampath Gowri, Belavendra Antonisamy, Debashish Danda
Summary: The combination therapy of methotrexate and sulfasalazine is effective in treating active axial spondyloarthritis patients over a 6-month period, regardless of the presence of peripheral arthritis. Improvements in ASAS20 response rates, decrease in NSAID use, and reduced need for biologicals were observed in both groups after treatment.
CLINICAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Jessica A. Walsh, Shaobo Pei, Gopi K. Penmetsa, Rebecca S. Overbury, Daniel O. Clegg, Brian C. Sauer
Summary: The study evaluated the performance of axSpA identification methods in the general VA population, including algorithm-based patient identification, sensitivities, positive predictive values, and F1 scores. Performance was estimated using unweighted and inverse probability weighted outcomes, showing a range of performance attributes and differences among the methods used.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Sjef M. van der Linden, Muhammad Asim Khan, Zhixiu Li, Heinz Baumberger, Hermine van Zandwijk, Kazim Khan, Peter M. Villiger, Matthew A. Brown
Summary: The occurrence of acute anterior uveitis (AAU) among first-degree relatives (FDRs) of axial spondyloarthritis (axSpA) patients should prompt screening for axSpA. The co-occurrence of chronic inflammatory back pain (CIBP) and pain/discomfort in the thoracic spine and anterior chest wall can further enhance clinical suspicion of axSpA among these FDRs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Anne Boel, Victoria Navarro-Compan, Desiree van der Heijde
Summary: The study aimed to assess the test-retest reliability of candidate instruments for the mandatory domains of the Assessment of Spondyloarthritis international Society (ASAS)-Outcome Measures in Rheumatology core set for axial spondyloarthritis (axSpA). The results showed good reliability for most instruments in evaluating disease activity in axSpA patients, with composite measures demonstrating higher reliability than single-item measures.
Article
Rheumatology
Atul A. Deodhar, Bernard Combe, Ana P. Accioly, Rebecca Bolce, Danting Zhu, Amanda M. Gellett, Aubrey Trevelin Sprabery, Gerd-Ruediger R. Burmester
Summary: This study reported the updated safety profile of ixekizumab up to 3 years in patients with PsA. The overall safety and tolerability of ixekizumab were consistent with the known safety profile in PsA patients, and no new or unexpected safety events were detected.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Philip J. Mease, Atul A. Deodhar, Desiree van der Heijde, Frank Behrens, Alan J. Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee
Summary: This study evaluated the efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active PsA. The results showed that treatment with deucravacitinib led to significant improvements in ACR-20 response, multiplicity-controlled secondary endpoints, and other exploratory efficacy measures. The treatment was well tolerated.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Orthopedics
Philip Mease, Atul Deodhar
Summary: Accurate diagnosis of nonradiographic axial spondyloarthritis is crucial for optimal treatment.
BMC MUSCULOSKELETAL DISORDERS
(2022)
Review
Rheumatology
Abhijeet Danve, Atul Deodhar
Summary: This review summarizes the progress in the pharmacological management of axial spondyloarthritis (axSpA), including newly approved biologic DMARDs. With advances in the understanding of the immunopathogenesis of this disease, new therapies have become available, which can substantially improve symptoms, signs and quality of life.
NATURE REVIEWS RHEUMATOLOGY
(2022)
Review
Rheumatology
Atul Deodhar, Suleman Bhana, Kevin Winthrop, Lianne S. Gensler
Summary: The rapid transmission of SARS-CoV-2 has raised concerns for patients with immune-mediated inflammatory diseases like spondyloarthritis who receive treatment with DMARDs. However, available data suggests that the infection rates among these patients are comparable to the general population. Vaccines are available and being developed to prevent SARS-CoV-2 infection, and evidence shows that COVID-19 vaccination in patients with SpA is safe and effective.
RHEUMATOLOGY AND THERAPY
(2022)
Article
Rheumatology
Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu
Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Sonam Kiwalkar, Richard Howard, Dongseok Choi, Atul Deodhar
Summary: This study aims to understand the diagnostic journey and barriers for US patients with nonradiographic axial spondyloarthritis (nr-axSpA). Interviews and surveys revealed that delayed diagnosis of nr-axSpA is common, with women and individuals in rural areas being more likely to experience delays. Impediments to timely diagnosis include chronic pain, episodic symptoms, other symptoms requiring medical consultation, and lack of knowledge about nr-axSpA among healthcare providers. Targeted education and research are needed to improve timely diagnosis.
CLINICAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Victoria Navarro-Compan, Xenofon Baraliakos, Marina Magrey, Andrew oestoer, Christopher D. Saffore, Manish Mittal, In-Ho Song, Fabiana Ganz, Jayne Stigler, Atul Deodhar
Summary: This study evaluated the impact of upadacitinib on patient-reported outcomes (PROs) in patients with ankylosing spondylitis (AS). It showed that upadacitinib can significantly improve disease activity, pain, fatigue, function, health-related quality of life (HRQoL), and work productivity in these patients.
RHEUMATOLOGY AND THERAPY
(2023)
Article
Rheumatology
Atul Deodhar, Natalie J. Shiff, Cinty Gong, Eric K. H. Chan, Elizabeth C. Hsia, Kim Hung Lo, Alianu Akawung, Lilianne Kim, Stephen Xu, John D. Reveille
Summary: IV-golimumab significantly improved fatigue symptoms in patients with AS and was associated with improvement in other AS symptoms. Golimumab provided long-term fatigue improvement in AS patients.
RHEUMATOLOGY AND THERAPY
(2023)
Article
Rheumatology
Christopher T. Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell
Summary: This study evaluated the efficacy and safety of guselkumab, an interleukin-23p19-subunit inhibitor, in patients with active psoriatic arthritis (PsA) who had previously used a tumor necrosis factor inhibitor (TNFi). The results showed that guselkumab provided sustained improvements across multiple domains in both TNFi-naive and TNFi-experienced patients with active PsA, and TNFi-naive patients were more likely to achieve treatment goals related to physical function and pain.
ACR OPEN RHEUMATOLOGY
(2023)
Review
Rheumatology
Atul Deodhar, Tejpal Gill, Marina Magrey
Summary: Axial spondyloarthritis (axSpA) is a chronic, immune-mediated disease characterized by inflammation in the axial skeleton and other non-musculoskeletal areas. HLA-B27 is strongly associated with axSpA and aids in diagnosis, but HLA-B27-negative patients face delays in diagnosis and often have poorly understood pathogenesis. This review discusses the role of HLA-B27 in axSpA diagnosis and pathogenesis and highlights other pathways and genes that may be involved in HLA-B27-negative patients. Understanding the clinical and pathological features of HLA-B27-negative axSpA patients will improve diagnosis, treatment, and outcomes.
ACR OPEN RHEUMATOLOGY
(2023)
Article
Rheumatology
Dennis McGonagle, Iain B. B. McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D. D. Chakravarty, Alexa P. P. Kollmeier, Xie L. L. Xu, Shihong Sheng, Stephen Xu, Christopher T. T. Ritchlin, Proton Rahman, Phillip J. J. Mease
Summary: The study found that a higher proportion of patients treated with guselkumab achieved resolution of dactylitis, and this resolution was associated with other important clinical outcomes.
ACR OPEN RHEUMATOLOGY
(2023)
Article
Rheumatology
Holly L. Rosenzweig, Emily E. Vance, Kofi Asare-Konadu, Kylie Koney, Ellen J. Lee, Atul A. Deodhar, Rouhin Sen, Liron Caplan, Ruth J. Napier
Summary: This study reveals a novel neutrophil-intrinsic role for Card9 in arthritogenic Th17 responses and the pathogenesis of AS. These data provide valuable utility in our future understanding of CARD9-specific mechanisms in spondyloarthritis.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S. Gensler
Summary: Bimekizumab (BKZ), a monoclonal antibody that inhibits IL-17F and IL-17A, demonstrated sustained efficacy in patients with axial spondyloarthritis (axSpA) at Week 52. The dual inhibition of IL-17A and IL-17F resulted in significant improvements compared to placebo and the safety profile was consistent with previous findings.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Atul Deodhar, Helena Marzo-Ortega, Joseph Wu, Cunshan Wang, Oluwaseyi Dina, Keith S. Kanik, Lara Fallon, Lianne S. Gensler
Summary: This study evaluated the efficacy and safety of tofacitinib in AS patients with prior bDMARD use. The results showed that tofacitinib had superior efficacy compared to placebo at week 16 and sustained efficacy up to week 48 in both bDMARD-naive and TNFi-IR patients.
ACR OPEN RHEUMATOLOGY
(2023)